ProQR Therapeutics NV Management Call Transcript
Thank you, operator, and good day, everyone. We appreciate you joining the call. I'm Sarah Kiely, Vice President of Investor Relations and Corporate Communications at ProQR. Today, we issued a press release announcing that going forward, we will focus exclusively on our RNA-editing platform technology, and will seek to partner our ophthalmology program. This press release can be found on our website at www.proqr.com.
With me today from the management team is Daniel de Boer, our Founder and CEO. Following Daniel's prepared remarks, we will have a Q&A session, which will include Daniel, along with Rene Beukema, our Chief Corporate Development Officer.
In order to include your question on today's call, we request that you use the phone numbers provided via the webcast link. During the call today, we will make forward-looking statements. There are risks and uncertainties associated with an investment in ProQR, which are described in detail in
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |